Market Overview

UPDATE: Piper Jaffray Upgrades Celgene Corporation to Overweight on Reduced Revlimid Reliance

Related CELG
US Stock Futures Flat; All Eyes On FOMC Decision
Deutsche Bank Is Bullish On Gilead Sciences, Inc. And Other Biotech Stocks
Yellen Swats Down Biotech, Social Media Stocks (Fox Business)

Piper Jaffray upgraded Celgene Corporation (NASDAQ: CELG) from Neutral to Overweight and raised the price target from $86.00 to $111.00.

Piper Jaffray noted, "We are upgrading CELG to Overweight from Neutral following positive top-line data from the Apremilast Phase III psoriasis studies and new 2017 guidance that supports a 25% annual EPS growth. We expect the streak of successful clinical studies and milestones, including Apremilast (psoriatic arthritis, psoriasis), Abraxane (lung cancer approval, melanoma, pancreatic), and pomalidomide (myeloma), to translate to meaningful top-line growth, lowering CELG's reliance on Revlimid performance."

Celgene Corporation closed at $85.73 on Monday.

Latest Ratings for CELG

DateFirmActionFromTo
Sep 2014Cantor FitzgeraldMaintainsBuy
Sep 2014SunTrust Robinson HumphreyInitiates Coverage on
Jul 2014Credit SuisseMaintainsOutperform

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (CELG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters